Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: osteopathic techniqueProcedure: Placebo
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 94
- Registration Number
- NCT02840890
- Locations
- 🇫🇷
CGFL, Dijon, France
Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Other: blood samplesOther: Urine samples
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 71
- Registration Number
- NCT02662621
- Locations
- 🇫🇷
CGFL, Dijon, France
Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer
Not Applicable
Active, not recruiting
- Conditions
- FDG PET
- Interventions
- Device: FDG PET
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 275
- Registration Number
- NCT02386709
- Locations
- 🇫🇷
Emilie REDERSTORFF, Dijon, France
NGS Genome Analysis in Personalisation of Lung Cancer Treatment
Not Applicable
Completed
- Conditions
- Lung Cancer
- Interventions
- Other: blood sample, biopsy
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 165
- Registration Number
- NCT02281214
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
Not Applicable
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Other: CBCTOther: fiducial marker (kV imaging)Radiation: IGRT Associated With IMRT
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 3
- Registration Number
- NCT02279693
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 32
- Registration Number
- NCT02090101
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, Burgundy, France
Brachytherapy for Recurrent Prostate Cancer
Phase 2
Completed
- Conditions
- Recurrent Prostate CancerBrachytherapy Remedial
- Interventions
- Radiation: brachytherapy remedial
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 30
- Registration Number
- NCT01956058
- Locations
- 🇫🇷
Centre GF Leclerc, Dijon, France
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma
Not Applicable
Completed
- Conditions
- GlioblastomaMetastatic Colorectal CancerBevacizumabCapillaroscopy
- Interventions
- Other: capillaroscopyOther: blood pressure measurement
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 47
- Registration Number
- NCT01810744
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Radiation: Simultaneous integrated boost intensity-modulated arctherapyDrug: Androgen deprivation
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 28
- Registration Number
- NCT01704027
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, Burgundy, France
Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy
Not Applicable
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 500
- Registration Number
- NCT01513408
- Locations
- 🇫🇷
CGFL, Dijon, France
© Copyright 2025. All Rights Reserved by MedPath